Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04756726 · ClinicalTrials.gov registry record · Phase 1

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

A Phase 1 study of Multiple Myeloma and Lymphoma, Non-Hodgkins, sponsored by C4 Therapeutics.

Active
Registry status
Phase 1
Development phase
224
Enrollment target
13
Study locations

NCT04756726 is a Phase 1 study of Multiple Myeloma and Lymphoma, Non-Hodgkins that is active but no longer recruiting, run by C4 Therapeutics. The registered enrollment target is 224 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (59% lower). The trial reports 13 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04756726, a Phase 1 study of Multiple Myeloma and Lymphoma, Non-Hodgkins, is active but no longer recruiting, sponsored by C4 Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
224 participants
Enrollment target
13
Study locations

Study Summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.

Conditions Studied

Multiple Myeloma Lymphoma, Non-Hodgkins

Interventions

  • DRUG Dexamethasone Oral
  • DRUG cemsidomide

Study Locations (13)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

New York

  • Mt Sinai Medical Center - New York
  • Memorial Sloan Kettering Cancer Center - New York

Arizona

  • Mayo Clinic - Phoenix

California

  • University of California-San Francisco - San Francisco

Colorado

  • Colorado Blood Cancer Institute (Sarah Cannon Research Institute) - Denver

Florida

  • Mayo Clinic - Jacksonville

Georgia

  • Emory University Hospital - Atlanta

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 224 participants
Start Date 2021-04-27
Est. Completion 2026-03-31
Phase Phase 1

Sponsor

C4 Therapeutics

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04756726

The ClinicalTrials.gov registry entry for NCT04756726 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (59% lower). The listed sponsor is C4 Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone Oral is the first listed.

NCT04756726 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Massachusetts, New York, Arizona.

Frequently Asked Questions

What is clinical trial NCT04756726 about?

NCT04756726 is a clinical study titled "Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma". The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma ...

What is the current status of trial NCT04756726?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 224 participants. The study started on 2021-04-27. Estimated completion is 2026-03-31.

What conditions does trial NCT04756726 study?

This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Non-Hodgkins.

What interventions are being tested in trial NCT04756726?

The interventions under investigation include: Dexamethasone Oral (DRUG), cemsidomide (DRUG).

Who is sponsoring clinical trial NCT04756726?

This trial is sponsored by C4 Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04756726 being conducted?

This trial has 13 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Lymphoma, Non-Hodgkins

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.